Zobrazeno 1 - 10
of 346
pro vyhledávání: '"Vamvakas, L."'
Autor:
Pallis, A.G. *, Karampeazis, A., Vamvakas, L., Vardakis, N., Kotsakis, A., Bozionelou, V., Kalykaki, A., Hatzidaki, D., Mavroudis, D., Georgoulias, V.
Publikováno v:
In Annals of Oncology November 2011 22(11):2448-2455
Autor:
Boukovinas, I., Souglakos, J., Hatzidaki, D., Kakolyris, S., Ziras, N., Vamvakas, L., Polyzos, A., Geroyianni, A., Agelidou, A., Agelaki, S., Kalbakis, K., Kotsakis, A., Mavroudis, D., Georgoulias, V.
Publikováno v:
In Lung Cancer 2009 63(1):77-82
Germline BRCA1 and BRCA2 loss-of-function variants have been linked to increased breast and ovarian cancer risk, with more than 5,000 distinct pathogenic variants being reported worldwide. Among individuals of Greek descent, the BRCA1/2 variant spect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::3beaf939f4d6a5128cef816e571d6989
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078244
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078244
Autor:
Pallis, A.G., Christofillakis, Ch., Tselepatiotis, E., Agelaki, S., Vamvakas, L., Souglakos, J., Vardakis, N., Kalykaki, A., Kotsakis, A., Argiraki, A., Mavroudis, D., Georgoulias, V.
Publikováno v:
In Lung Cancer 2007 55(1):101-107
Autor:
Boukovinas, I. *, Androulakis, N., Vamvakas, L., Papakotoulas, P., Ziras, N., Polyzos, A., Kalykaki, A., Kotsakis, A., Xenidis, N., Gioulmbasanis, I., Mavroudis, D., Georgoulias, V.
Publikováno v:
In Annals of Oncology November 2006 17(11):1687-1692
Autor:
Brunello, A., Basso, U. *, Pogliani, C., Ghiotto, C., Koussis, H., Lumachi, F., Iacobone, M., Vamvakas, L., Monfardini, S., Jirillo, A.
Publikováno v:
In Annals of Oncology August 2005 16(8):1276-1282
Autor:
Yiangou, K., Hadjisavvas, A., Agelaki, S., Aggouraki, D., Androulakis, N., Bozionelou, V., Drositis, I., Kalmpakis, K., Kalykaki, A., Kontopodis, E., Kotsakis, A., Politaki, E., Saloustrou, G., Vamvakas, L., Vardakis, N.K., Georgoulias, V., Mavroudis, D., Michailidou, K., Saloustros, E.
Publikováno v:
In Annals of Oncology May 2022 33 Supplement 3:S189-S189
Background This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma. Methods Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and flu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::b4343ff89413a2b0e1b26bc798357a46
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107987
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107987
Metastatic triple-negative breast cancer lacks a standard therapeutic strategy and represents an unmet need for novel therapies. We conducted a phase II study to evaluate the weekly paclitaxel/carboplatin/bevacizumab combination. Forty-six patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::154f4eda955cf10b9483a2991c16251b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086505
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086505
Objectives To compare first-line treatment with docetaxel plus gemcitabine (DG) versus gemcitabine (G) in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC). Patients and Methods Chemotherapy-naïve patients with inoperable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::8e2987f6f3d0b477c6394fac683f4227
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3126659
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3126659